CD19 and cancer: Preclinical research has shown that combining CD19-CAR-NK and rituximab (anti-CD20) can help to overcome CD19-antigen, preferentially sparing CD19+ healthy B cells (versus cancer cells), and boost CAR-NK degranulation and cytokine production capacity [223].